Literature DB >> 27443162

Use of signals and systems engineering to improve the safety of warfarin initiation.

G Hyun1, J Li1, A R Bass2, A Mohapatra1, S C Woller3, H Lin1, C Eby1, G A McMillin4, B F Gage5.   

Abstract

Warfarin-dosing algorithms combine clinical factors and dosing history with the current international normalized ratio (INR) to estimate the therapeutic warfarin dose. Unfortunately, these approaches can result in an overdose if the INR is spuriously low. Our goal was to develop an alert mechanism based on prior INRs in addition to the current INR. Using data from the Genetics InFormatics Trial (GIFT) of Warfarin to Prevent DVT, we analyzed warfarin dose estimates for days 3 through 11 that were ≥10 % higher than an average of the previous two dose estimates. We fit a stepwise mixed model to current and prior dose estimates, and subsequently compared the root-mean-square-error (RMSE) in predicting the final therapeutic dose using the GIFT algorithm versus the mixed model. From 861 dosing records (obtain from 556 patients), 646 dosing records (75 %) were randomly selected for the derivation cohort and 215 dosing records (25 %) for the validation cohort. Using one prior dose estimate improved the accuracy of the warfarin dose estimate. Compared to a dose estimate based on current INR (GIFT algorithm), the mixed model reduced the RMSE in the derivation cohort by 0.0015 mg/day (RMSE 0.2079 vs. 0.2094; p = 0.039). In the validation cohort, the RMSE reduction was not significant. A mixed model of dose estimates based on the current and most recent INRs shows potential to improve the safety of warfarin dosing. Clinicians should be cautious about aggressively escalating the warfarin dose after an INR that is lower than expected.

Entities:  

Keywords:  Dosing algorithm; INR; Overdose; Patient safety; Warfarin

Mesh:

Substances:

Year:  2016        PMID: 27443162      PMCID: PMC5153371          DOI: 10.1007/s11239-016-1402-z

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  8 in total

1.  Emergency hospitalizations for adverse drug events in older Americans.

Authors:  Daniel S Budnitz; Maribeth C Lovegrove; Nadine Shehab; Chesley L Richards
Journal:  N Engl J Med       Date:  2011-11-24       Impact factor: 91.245

2.  Tailoring warfarin induction doses to reflect individual and disease-specific factors.

Authors:  Walter Ageno; Alessandro Squizzato; Francesco Dentali; Mark Crowther
Journal:  Am J Med       Date:  2005-02       Impact factor: 4.965

3.  The effectiveness of warfarin dosing from a nomogram compared with house staff dosing.

Authors:  Peter D Asnis; Michael J Gardner; Anil Ranawat; Anne H Leitzes; Margaret G E Peterson; Anne R Bass
Journal:  J Arthroplasty       Date:  2007-02       Impact factor: 4.757

4.  Comparison of a single end point to determine optimal initial warfarin dosing (5 mg versus 10 mg) for venous thromboembolism.

Authors:  Rene Quiroz; Marie Gerhard-Herman; Joshua M Kosowsky; Stacia M DeSantis; Nils Kucher; Sylvia C McKean; Samuel Z Goldhaber
Journal:  Am J Cardiol       Date:  2006-06-28       Impact factor: 2.778

5.  Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.

Authors:  Benjamin D Horne; Petra A Lenzini; Mia Wadelius; Andrea L Jorgensen; Stephen E Kimmel; Paul M Ridker; Niclas Eriksson; Jeffrey L Anderson; Munir Pirmohamed; Nita A Limdi; Robert C Pendleton; Gwendolyn A McMillin; James K Burmester; Daniel Kurnik; C Michael Stein; Michael D Caldwell; Charles S Eby; Anders Rane; Jonatan D Lindh; Jae-Gook Shin; Ho-Sook Kim; Pantep Angchaisuksiri; Robert J Glynn; Kathryn E Kronquist; John F Carlquist; Gloria R Grice; Robert L Barrack; Juan Li; Brian F Gage
Journal:  Thromb Haemost       Date:  2011-12-21       Impact factor: 5.249

6.  Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.

Authors:  Virginie Siguret; Isabelle Gouin; Matthieu Debray; Christine Perret-Guillaume; Jacques Boddaert; Isabelle Mahé; Valérie Donval; Marie-Laure Seux; Marjolaine Romain-Pilotaz; Mathilde Gisselbrecht; Marc Verny; Eric Pautas
Journal:  Am J Med       Date:  2005-02       Impact factor: 4.965

7.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

Authors:  P A Lenzini; G R Grice; P E Milligan; M B Dowd; S Subherwal; E Deych; C S Eby; C R King; R M Porche-Sorbet; C V Murphy; R Marchand; E A Millican; R L Barrack; J C Clohisy; K Kronquist; S K Gatchel; B F Gage
Journal:  J Thromb Haemost       Date:  2008-07-24       Impact factor: 5.824

8.  Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.

Authors:  E J Do; P Lenzini; C S Eby; A R Bass; G A McMillin; S M Stevens; S C Woller; R C Pendleton; J L Anderson; P Proctor; R M Nunley; V Davila-Roman; B F Gage
Journal:  Pharmacogenomics J       Date:  2011-05-24       Impact factor: 3.550

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.